J&J looks to sell feminine products unit; Pfizer nabs broader use for Prevnar 13;

@FiercePharma: Another Bayer drug gets the eye from French regulators: Acne drug/BCP Diane-35 linked to 4 deaths, ANSM says. More | Follow @FiercePharma

 @AlisonBFierce: GSK formed a joint venture in India to produce a 6-in-1 vaccine that will immunize children in developing countries. News | Follow @AlisonBFierce

> Johnson & Johnson ($JNJ) is shopping its feminine products business, The Wall Street Journal reports, as part of an effort to shed bits of the company that don't fit its growth strategies. Report

> Pfizer ($PFE) won another new use for its Prevnar 13 vaccine, broadening its market to children 6 years to 17 years old; the pneumococcal shot is now Pfizer's leading product. Report

> Merck ($MRK) won approval to market its overactive bladder patch Oxytrol over the counter. Report

> The new Actavis, created with Watson Pharmaceuticals' ($WPI) buyout of the Swiss generics maker Actavis, terminated an insulin marketing deal with biosimilars maker Bioton. Report

> The U.S. has asked for an exemption from new European rules for active pharmaceutical ingredients. Report

> Mexico's Genomma bought the Argentine painkiller brand Tafiral for $26.94 million. Report

Medical Device News

 @FierceMedDev: UNC team identifies Dx to spot worsening macular degeneration. News | Follow @FierceMedDev

 @MarkHFierce: The Netherlands' Medisse nailed down a $3.5M US Series B to fund development of a bioresorbable material for implants. Release | Follow @MarkHFierce

 @DamianFierce: That rumored Quintiles IPO may finally be around the corner, anon. sources tell Reuters, Bloomberg. News | Follow @DamianFierce

> Medisse raises $3.5M for new med device biomaterial. Article

> Given Imaging is no longer selling itself, but an EU investor wants a piece. More

Biotech News

 @FierceBiotech: Keryx shares soar on upbeat PhIII results for CKD drug Zerenex. Article | Follow @FierceBiotech

@JohnCFierce: New bidness model: VCs launch another biotech with late-stage R&D model for Big Pharma--(think SFJ). More | Follow @JohnCFierce

@RyanMFierce: FDA called out in study of smartphone apps for melanoma. Report | Follow @RyanMFierce

> Idenix moves out of FDA limbo with J&J hep C combo pact. Story

> Takeda grabs long-awaited U.S. approval for diabetes drug Nesina. News

Biotech IT News

> FDA called out in study of smartphone apps for melanoma. Article

> Big Data analysis takes on childhood brain cancer. Story

> Hopkins mines Twitter for real flu cases in real time. More

> NIH supports Parkinson's research with online collaboration. Item

CRO News

> Is Quintiles finally going public? Article

> Covance soars on 60% income growth in Q4. Report

> GVK teams up with Endo on early-stage pain drug. Story

> Indian Supreme Court wants answers on clinical trials. More

And Finally... A flood of lawsuits challenges new U.S. rules requiring employer-provided health plans to provide contraceptives at no cost to their members. Report (sub. req.)